2-(2-BROMOPHENYL)PIPERIDINE HYDROCHLORIDE
- $310 - $497.08
- Product name: 2-(2-BROMOPHENYL)PIPERIDINE HYDROCHLORIDE
- CAS: 1177325-72-2
- MF: C11H15BrClN
- MW: 276.6005
- EINECS:
- MDL Number:MFCD08752920
- Synonyms:2-(2-BROMOPHENYL)PIPERIDINE HYDROCHLORIDE;2-(2-Bromophenyl)piperidine, HCl;2-(2-B2-(2-Bromophenyl)piperidine hydrochlorideromophenyl)piperidine hydrochloride
4 prices
Selected condition:
Brand
- American Custom Chemicals Corporation
- Chemenu
- Crysdot
- TRC
Package
- 5MG
- 500mg
- 1g
- ManufacturerAmerican Custom Chemicals Corporation
- Product numberHCH0033483
- Product description2-(2-BROMOPHENYL)PIPERIDINE HYDROCHLORIDE 95.00%
- Packaging5MG
- Price$497.08
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM315437
- Product description2-(2-Bromophenyl)piperidinehydrochloride 95%
- Packaging1g
- Price$400
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11340442
- Product description2-(2-Bromophenyl)piperidinehydrochloride 95+%
- Packaging1g
- Price$424
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberB998315
- Product description2-(2-Bromophenyl)piperidineHydrochloride
- Packaging500mg
- Price$310
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
American Custom Chemicals Corporation | HCH0033483 | 2-(2-BROMOPHENYL)PIPERIDINE HYDROCHLORIDE 95.00% | 5MG | $497.08 | 2021-12-16 | Buy |
Chemenu | CM315437 | 2-(2-Bromophenyl)piperidinehydrochloride 95% | 1g | $400 | 2021-12-16 | Buy |
Crysdot | CD11340442 | 2-(2-Bromophenyl)piperidinehydrochloride 95+% | 1g | $424 | 2021-12-16 | Buy |
TRC | B998315 | 2-(2-Bromophenyl)piperidineHydrochloride | 500mg | $310 | 2021-12-16 | Buy |
Properties
Safety Information
Symbol(GHS): | ||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | |||||||||||||||||||||||||||||||||||
Hazard statements: |
|
|||||||||||||||||||||||||||||||||||
Precautionary statements: |
|